“Pharmaceutical Product Divestiture and Acquisition” will be the topic of the Tuesday, Nov. 17, Life Sciences Lunch Series seminar at Barnes & Thornburg, 11 S. Meridian St., Indianapolis.

Many pharmaceutical startups are developing drugs that, although high in revenue for the average-size company and very attractive for a startup, are not the blockbusters that keep big pharma profitable. Pharmaceutical giants are re-evaluating their pipelines and are seeking to sell products that no longer fit their business strategies. This program will look at what it means from a regulatory standpoint for these products to get to market and will cover product divestiture from the viewpoints of big pharma companies and startup companies.

Speakers will be Reed Tarwater Ph.D., RAC, director of pharmaceutical consulting services, The Anson Group; P. Ron Ellis, president and CEO, Endocyte Inc. and Pete Robins, Eli Lilly and Co.

The program will be from 11:30 am to 1 pm with video conferencing available at Barnes & Thornburg offices in South Bend, Fort Wayne and Elkhart and cooperating facilities Bloomington, Evansville, Hammond, Merrillville, Muncie, New Albany, Richmond, Terre Haute and West Lafayette. There is a $10 attendance fee in Indianapolis. A box lunch will be available at Barnes & Thornburg offices, or attendees may bring their own lunch. Please register at www.ihif.org/conference/register/14